– USA, CA – CRISPR QC announced the appointment of Dr. Toby Richardson (Ph.D.) to its board of directors, effective on October 26th, 2022.
“CRISPR QC has already started proving that the unique capabilities of our CRISPR Analytics Platform can interrogate previously unknowable dimensions of gene editing that is translating into real value for our customers,” said CEO, Ross Bundy. “The next step in our development is taking this unique insight and building greater depth to our data and analytics capabilities. Dr. Richardson’s extensive experience in this space will be key to guiding this emerging aspect of our business.”
About Dr. Toby Richardson
Dr. Richardson co-founded Denovium inc in 2018, a company that used state-of-the-art deep learning technology to solve the big data issues facing the pharmaceutical and industrial biotech sectors. Toby brings over two decades of industrial experience leading bioinformatics teams and developing and commercializing genomics software. Toby has served on the board of Agracast and is a scientific advisor to several Biotech companies. He is the author of more than 30 peer-reviewed publications and is an inventor of more than 20 patents.
“I am honored to join CRISPR QC’s board. CRISPR QC’s CRISPR analytics platform is one of a kind, with many new types of data-driven insights that therapeutics, biotech, and agtech companies will greatly benefit from. I look forward to contributing to CRISPR QC’s data strategy to realize its full potential,” said Dr. Toby Richardson.
Dr. Richardson received his Ph.D. in Drug Metabolism from the University of Surrey.
About CRISPR
CRISPR has the potential to be the defining technology of the 21st century. CRISPR is showing promise to cure uncurable diseases previously, secure our food supply, and much more. However, these advancements are not without risks or blind spots. The need for quality control and insight has grown concurrently with the advances and successes of CRISPR gene editing. At CRISPR QC we utilize our CRISPR Analytics Platform, powered by the CRISPR-Chip, to optimize and de-risk gene editing outcomes by providing a new form of insight into CRISPR.
About CRISPR QC
At CRISPR QC, we’re working to empower the scientists, researchers, and doctors at the front lines of the genetic engineering revolution. Our CRISPR Analytics Platform provides the data and insights they need to power the safest, most efficacious gene editing outcomes.
For more information: https://www.crisprqc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.